NeoPhore Ltd, a small molecule neoantigen immuno-oncology company, has appointed Michael Shih as chief executive officer after closing a Series B financing round supported by Bristol Myers Squibb Co. An attorney by training, Mr Shih brings almost 20 years of experience in business development and deal making in the pharmaceutical industry. He was most recently vice president of corporate development at Kite Pharma, and prior to that was senior vice president, head of business development at Biogen Inc.
NeoPhore is developing a pipeline of small molecule drugs targeting proteins across the mismatch repair (MMR) pathway for immunotherapies to treat cancer. The funding is enabling NeoPhore to complete pre-clinical studies to deliver a candidate drug for its lead PMS2 cancer programme in 2025.
NeoPhore announced the appointment on 16 December 2024.
Copyright 2025 Evernow Publishing Ltd.